Pre-Congress Workshops: Tuesday, October 21, 2025
2 CONCURRENT 4-hr AFTERNOON SESSIONS
• Hands-On Demonstration Workshop #1: Liver Perfusion  
• Hands-On Demonstration Workshop #2: Robotic Surgery 

Day 1: Wednesday, October 22, 2025

SESSION 1: General Principles
•Bleeding control in minimally invasive liver surgery
•Techniques in advanced MIS Liver Surgery – benefits and limitations
•Anatomic liver resection in MIS Liver Surgery
•Intraglissionian vs. Extraglissionian approach of the pedicle, when and why
•How to control the pressure, managing venous injury

SESSION 2: How I Do It – General Principles
•How to do a safe right and left laparoscopic hepatectomy
•Advanced Laparoscopic liver resections in patients with portal hypertension
•How to do a safe right and left robotic hepatectomy
•How to do robotic (Alpps Procedure) staged hepatectomy for different etiologies (CRLM vs HCC vs CCC)
•Advanced robotic liver resections including vascular and bile duct resections
•State of the Art Lecture: Robotic Liver Donor Liver transplant. Is it the Future?

SESSION 3: Liver Transplantation 
• Minimally invasive living donor hepatectomy – Is this standard of care? 
• Implanting livers with minimally invasive techniques – will this ever take off? 
• How to prevent intraoperative complications 

SESSION 4: How I Do It – Pancreas 
•How to do a safe MIS distal pancreatectomy with ad without spleen preservation
•How to do a safe MIS Whipple procedure
•MIS pancreas resections including vascular resection

Day 2: Thursday, October 23, 2025

SESSION 5: Innovations in Hepatocellular Carcinoma Care
• Refining HCC imaging – What is the future? 
• AI to diagnose and stage HCC on imaging – Are we there yet? 
• Advanced IR imaging techniques in HCC diagnosis and prognosis. 

SESSION 6: Tumor Board Presentations 
•Case 1: Resectable HCC in Child B cirrhosis (East vs West experience)
•Case 2: Advanced HCC with vascular involvement successfully down-staged to resection with Immuno/IR/SBRT (Neoadjuvant)
•Case 3: Super advanced HCC Neoadjuvant Immuno to treatment
•State of the Art Lecture: Global Perspectives in HCC treatment

SESSION 7: Early-Stage HCC – Maximizing Outcomes with Neoadjuvant and Adjuvant Therapy 
•Optimizing treatment pathways: Neoadjuvant approaches in early-stage HCC: upfront vs LRT vs systemic vs combo approaches
•Adjuvant therapy in HCC: Preventing recurrence and improving survival or too much risk with little data?

SESSION 8: Intermediate-Stage HCC – Resection vs. Transplantation 
•Surgical strategies: Resection as a viable DS strategy in giant and multifocal HCC.
•The Transplantation Paradigm: Where do we draw the line? Expanding role and considerations.
•Surgery with portal hypertension. Preoperative assessment and evaluation of extent of portal hypertension. True morbidity/mortality in Child B cirrhosis undergoing resection.

SESSION 9: Macrovascular Invasion: Balancing Systemic and Curative Options & Biomarkers, Liquid Biopsy: Guiding Precision Medicine in HCC 
•Balancing systemic and curative options
     > Macrovascular invasion in HCC: Challenges and treatment implications
     > Systemic therapies: Advancements in targeted and immunotherapies
     > Curative approaches: Surgery and locoregional therapies in the era of macrovascular invasion
•Biomarkers, liquid biopsy: Guiding precision medicine in HCC
     > Alpha-fetoprotein ad beyond biomarkers in HCC diagnosis and prognosis

Day 3: Friday, October 24, 2025

SESSION 10: Intrahepatic Cholangiocarcinoma

SESSION 11: Hilar Cholangiocarcinoma

SESSION 12: Pancreatic Cancer

SESSION 13: Controversies in the Management of Pancreatic Cancer

Day 4: Saturday, October 25, 202

SESSION 15: Management of Initially Unresectable Liver Metastases

SESSION 16: Joint ISLS & DEI in Transplant Session & ISLS Closing